Recursion Pharmaceuticals, 8-K (1.01, 2.02, 7.01, 8.01, 9.01): entered into a material agreement

Recursion said Sanofi optioned a first immunology development candidate, triggering a $10 million milestone payment and bringing collaboration payments received to $144 million; the candidate is planned to enter Phase 1 trials in 2027, with over $300 million in potential additional milestones and royalties.